Esperion Therapeutics Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of Esperion Therapeutics Insights data
| Headline | Published | Journalists |
|---|---|---|
| Deserunt mollit sunt Lorem laborum do id aliqua dolore | 28 Mar 2019 | Lorem |
| Esperion’s bempadoic acid leaves experts unfazed with chance fatalities in Phase III trial, future efficacy probable | 11 May 2018 | Hannah Wilgar |
| Esperion’s ETC-1002 unlikely to replace PCSK9s inhibitors for HeFh and ASCVD in patient majority – experts | 04 Nov 2015 | Alexandra Thompson |
| Esperion’s lipid-lowering ETC-1002 warrants CVOT ahead of approval, trial design debated – experts | 04 Nov 2015 | Alexandra Thompson |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer